Today: 28 February 2026
Subscribe
Browse Category

NASDAQ:BDRX 10 December 2025

Biodexa Pharmaceuticals (NASDAQ: BDRX) Stock on December 10, 2025: Violent Rally, Phase 3 FAP Progress and What 2026 Might Hold

Biodexa Pharmaceuticals (NASDAQ: BDRX) Stock on December 10, 2025: Violent Rally, Phase 3 FAP Progress and What 2026 Might Hold

Biodexa Pharmaceuticals (NASDAQ: BDRX) closed at $4.09 on December 9, down 53.5% from the prior session, after wild swings that saw the stock trade between $4.00 and $7.60 intraday. The company is advancing a Phase 3 trial in a rare inherited cancer syndrome and exploring new financing. Its float remains under 670,000 ADSs, fueling extreme volatility. Market cap stands near $5.5 million.
10 December 2025
··
Top U.S. Stock Gainers Today (Dec. 10, 2025): ASPC, ENVB, BDRX, HSPO, BRZE Surge Ahead of Fed Decision

Top U.S. Stock Gainers Today (Dec. 10, 2025): ASPC, ENVB, BDRX, HSPO, BRZE Surge Ahead of Fed Decision

A SPAC III Acquisition (ASPC) surged over 100% pre-market Dec. 10, trading between $25 and $31 after sharp gains in after-hours. Enveric Biosciences (ENVB) and Biodexa Pharmaceuticals (BDRX) also posted triple- and double-digit percentage gains. Major U.S. index futures were little changed ahead of the Federal Reserve’s final 2025 rate decision. Speculative micro-caps and SPACs led early trading volatility.
10 December 2025
··········
Top Pre‑Market Gainers Today, December 10, 2025: ASPC, ENVB, BDRX and APVO Lead Fed‑Day Frenzy

Top Pre‑Market Gainers Today, December 10, 2025: ASPC, ENVB, BDRX and APVO Lead Fed‑Day Frenzy

A SPAC III Acquisition Corp. surged over 219% pre-market Wednesday, leading U.S. gainers as traders await the Federal Reserve’s final 2025 policy decision. Nasdaq 100, S&P 500, and Dow futures ticked higher, while the 10-year Treasury yield hovered near 4.18%. Silver traded above $61 an ounce. Other top pre-market movers included Enveric Biosciences, Biodexa Pharmaceuticals, and Ashford Hospitality Trust.
10 December 2025
··········
Go toTop